TY - JOUR
T1 - Phase i trial of m-bacod and granulocyte macrophage colony stimulating factor in hiv-associated non-hodgkin’s lymphoma
AU - Walsh, Christina
AU - Wernz, James C.
AU - Levine, Alexandra
AU - Rarick, Mark
AU - Willson, Esther
AU - Melendez, Debbie
AU - Bonnern, Eric
AU - Thompson, James
AU - Shelton, Brent
PY - 1993/3
Y1 - 1993/3
N2 - The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.
AB - The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.
KW - Colony stimulating factors
KW - HIV
KW - Non-Hodgkin’s lymphoma
UR - http://www.scopus.com/inward/record.url?scp=0027503010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027503010&partnerID=8YFLogxK
M3 - Article
C2 - 7680712
AN - SCOPUS:0027503010
SN - 1525-4135
VL - 6
SP - 265
EP - 269
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 3
ER -
